Background-The challenge of angiogenesis science is that stable sustained vascular regeneration in humans has not been realized despite promising preclinical findings. We hypothesized that angiogenic therapies powerfully self-regulate by dynamically altering tissue characteristics. Induced neocapillaries increase drug clearance and limit tissue retention and subsequent angiogenesis even in the face of sustained delivery. Methods and Results-We quantified how capillary flow clears fibroblast growth factor after local epicardial delivery.
S timulation of neovascularization with angiogenic growth factors might reduce myocardial infarct size and improve cardiac function 1 and peripheral tissue 2 perfusion. Yet, impressive results in tissue culture and animal studies [3] [4] [5] [6] [7] have not been sustained in clinical trials. 8 -11 Intravascular delivery of angiogenic factors is convenient but challenged by the requirements for high doses and long residence times. 8, 10 Cell and gene injections might provide a continuous source of growth factor, and intramyocardial or pericardial delivery has elevated local tissue drug concentrations with lower systemic exposure in animal models. 12 However, the promise of symptomatic improvement and increased capillary density seen in early clinical trials with intramyocardial injections of fibroblast growth factor (FGF) after coronary artery bypass grafting 13 has not endured in larger clinical trials, and clinical outcomes in general with local growth factor delivery have been mixed. 9,14 -18 
Clinical Perspective on p 2935
Some have postulated that myocardial growth factor concentrations, drug residence time, or both were inadequate for sustained angiogenesis despite controlled release delivery. 19 However, the local pharmacokinetic processes governing the uptake and distribution of growth factors in highly vascularized tissues such as myocardium remain ill defined. It is therefore possible that the reverse is true and that growth factor concentrations were actually more than sufficient initially. We hypothesized that local delivery can induce neocapillary growth but, in doing so, changes the balance between drug delivery and microvascular drug clearance to favor the latter, so that the very pharmacological efficacy of these compounds limits their biological effect.
We used a series of ex vivo analytical and in vivo experimental animal models to quantify how growth factors distribute within vascularized tissue and how neovascularization after delivery of angiogenic growth factors affects their pharmacokinetics and efficacy. These studies strongly suggest that angiogenesis is powerfully self-regulating in that the capillaries induced by angiogenic drug therapy may increase clearance rates, limiting tissue levels of growth factor and subsequent angiogenesis even with sustained delivery.
Methods

Ex Vivo Myocardial Drug Delivery With and Without Perfusion
Sprague Dawley rats (0.5 to 0.6 kg) were anesthetized with 35 mg/kg ketamine and 5 mg/kg xylazine and anticoagulated with 1000 U heparin SC before to CO 2 euthanasia. The aorta was cannulated and the heart was retrograde perfused with cardioplegia (osmolality, 289Ϯ5% mOsm/kg H 2 O) composed of Krebs-Henseleit buffer (Sigma-Aldrich, St Louis, Mo) with high potassium (30 mmol/L KCl) and 4% BSA (Sigma-Aldrich) to establish diastolic arrest. The heart was excised and perfused at 95 mm Hg. Coronary flow was monitored periodically and ranged from 8 to 10 mL/min throughout the experiment. The perfusate was oxygenated by a foam bubble oxygenator with 95% O 2 /5% CO 2 at 37°C. Samples also were examined in the absence of coronary perfusion to eliminate other effects. Here, the aorta was cannulated and flushed with perfusate. As blood cleared from the circulation, coronary outflow from the coronary sinus was stopped by clamping the right atrium and pulmonary artery, ensuring the patency of myocardial capillaries and ensuring that the only difference between the control and perfused cases was coronary perfusion. The entire configuration resided within an enclosed box with 100% humidity. We ascertained myocardial viability at 6 hours by quantitatively documenting no additional tissue edema on hematoxylin and eosin-stained sections. Experimental protocols were in accordance with National Institutes of Health guidelines for the humane care and use of laboratory animals and the MIT Committee on Animal Care.
Texas Red-FGF2 (TR-FGF2; 17 kDa; 5.88ϫ10 Ϫ2 mol/L) or Texas Red-labeled FGF2 conjugated to sucrose octasulfate (SOS) complex [TR-(FGF2) 2 -SOS complex; Ϸ35 kDa; 2.86ϫ10 Ϫ2 mol/L] was delivered to the rat myocardium from a drug-releasing chamber affixed to the anterior epicardial surface by a cyanoacrylate-based surgical adhesive (Glustitch, Point Roberts, Wash). Hearts were placed on a shaker at 100 rpm to ensure a well-mixed epicardial drug source. A core of myocardial tissue in contact with and immediately adjacent to the drug source was harvested 6 hours later with an 8-mm-diameter biopsy punch (Miltex, York, Pa). Tissue cores were cryosectioned (Leica CM1850, Leica, Germany) perpendicular to the epicardium for quantitative epifluorescence imaging (Leica DMRA2 microscope; Hamamatsu C4742-95 camera, Bridgewater, N.J.; MetaMorph software, Sunnyvale, Calif; Texas Red filter set). Because the fluorescent intensity of TR-FGF2 is linearly proportional to fluorophore, 20 total drug deposition in the absence (M diff ) or presence (M diff-clear ) of coronary perfusion was calculated by summing fluorescence intensities in the spatial distributions. Percent clearance of drug from coronary perfusion is given by Equation M1:
In Vivo Myocardial Drug Delivery
Rabbits (New Zealand White, 3 to 3.5 kg) received an intramuscular injection of 35 mg/kg ketamine and 5 mg/kg xylazine, inhaled isoflurane anesthesia (1% to 3%), and positive pressure ventilation via a 3.0-mm endotracheal tube. The chest was shaved and sterilely prepared with Betadine and alcohol. A left thoracotomy was performed after local lidocaine injection. A clamp kept the chest open, and a small opening in the pericardium was created with care to minimize pericardial damage. The left anterior descending coronary artery was ligated. Ischemia was confirmed by ST-segment elevation on simultaneous continuous ECG. Sodium alginate polymeric de-vices sustain-releasing 35 S-FGF1 from encapsulated heparin Sepharose beads (see the Materials section in the online-only Data Supplement) were placed in the pericardial space, and the pericardiotomy suture was repaired to prevent leakage. The thoracotomy and skin incision were closed. Positive end-expiratory pressure ventilation and a negative pressure chest tube prevented pneumothorax. Analgesia was with 0.03 mg/kg buprenorphine SC injections every 8 hours for the first 72 hours. Control animals received alginate-encapsulated heparin Sepharose beads without FGF. Hearts were harvested 2, 8, 16, and 31 days after surgery, and the aortas were cannulated, flushed retrogradely with PBS, and snap-frozen in liquid nitrogen.
Quantification of In Vivo FGF1 and Blood Vessel Distribution
Two frozen myocardial cores were excised adjacent to the polymeric devices with an 8-mm-diameter biopsy punch (Miltex). One core was mounted and cryosectioned (Leica CM1850) into 100-m sections parallel to the epicardium. Sections were digested in 1 mL solvable tissue solubilizer (Perkin Elmer, Waltham, Mass) at 60°C overnight before radioactivity quantification (2500TR Liquid Scintillation Analyzer, Packard). The discrete spatial FGF1 concentration data were fit to the exponential profile implied by Equation 4 given in the Table with GraphPad software (Prism 5, La Jolla, Calif). The fit was used to estimate the penetration depth (x 90 ), defined as the distance from the source to 90% drop-off threshold, as x 90 ϭᐉϫln (10) . The other tissue core was cryosectioned into 10-m-thick sections in the transmural direction. Sections were fixed for 5 minutes with 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, Pa), washed for 30 seconds with cold acetone (Sigma-Aldrich, St. Louis, Mo), incubated in blocking serum (200 L 1% chicken serum for 1 hour at 37°C) and then in goat anti-PECAM-1 IgG (Santa Cruz Biotechnology, Santa Cruz, Calif; 200 L of 1:50 dilution for 2 hours at 37°C), washed 3 times in 0.1% Tween 20 in PBS, incubated again with Alexa Fluor 488 chicken anti-goat IgG (Invitrogen, Carlsbad, Calif; 200 L of 1:200 dilution for 2 hours at 37°C), washed 3 times in Tween 20/PBS, coverslip mounted, and imaged immediately with a fluorescence microscope (Leica DMRA2, FITC filter set). The images were thresholded to maximize the signal-to-noise ratio with Matlab (MathWorks, Natick, Mass), yielding binary images of vessel distribution. Neovascular formation of tissue regions within 500 m from the epicardial source was quantified by computing the tissue area fraction stained by
Table. Continuum Pharmacokinetic Model Equations for Epicardial Drug Delivery
CϭC PECAM-1 (total number of pixels with PECAM-1 stain divided by the total number of pixels of tissue area).
Statistical Analysis
All data are presented as meanϮSEM, except values for the clearance rate constants (k), which are reported as meanϮpropagated SE. Propagated errors, s k , were calculated with this formula: 
Results
FGF Distribution Is Limited by Myocardial Perfusion
Drug transport through and deposition within tissues are governed by molecular weight-dependent processes such as diffusion and convection and physicochemical attributes such as binding, partitioning, and metabolism. [21] [22] [23] We examined the effects of capillary perfusion on myocardial growth factor transport in rat hearts incubated at constant epicardial source concentrations ( Figure I in the online-only Data Supplement) with and without controlled coronary flow. When delivered to the ex vivo myocardium in the absence of flow, TR-FGF2 distributed via diffusion to a penetration depth of 66 m in 6 hours ( Figure 1 ). Restoration of coronary perfusion reduced TR-FGF2 penetration depth Ͼ2-fold to 28 m, localizing growth factor closer to the epicardial drug source ( Figure 2 ).
Drug Diffusivity, Transendothelial Permeability, and Vessel Density Influence Local Drug Distribution and Deposition
We examined the impact of coronary flow on drug penetration within the context of a continuum pharmacokinetics model of drug diffusion in the face of microvascular clearance (Equation 1 in the Table) . In the absence of perfusion, the growth factor distribution curve mimics the analytical solution of the diffusion equation (Equation 3 in the Table) with an apparent diffusivity of 0.021Ϯ0.001 m 2 /s for TR-FGF2. This value is 4 orders of magnitude smaller than the reported diffusivity of FGF in free aqueous solution, 24 reflecting the impact of steric hindrance and binding within tissues. TR is small (600 Da) and hydrophilic. Its diffusion is significantly higher than FGF in heparin sulfate proteoglycan-rich myocardium, and detected fluorescence is likely specific for TR-FGF-2. In the presence of coronary perfusion, the capacity of capillaries to clear drugs is restored, and the distribution of TR-FGF2 at 6 hours approaches an exponential steady-state profile consistent with an apparent clearance rate constant: kϭ1.15Ϯ0.06ϫ10 Ϫ4 s Ϫ1 (Equation 4 in the Table) . Given a normal myocardial capillary density of Ϸ12.9% 25 and FGF2 aqueous diffusivity of 2.2ϫ10 2 m 2 /s, 24 our estimate of the clearance rate constant of FGF2 implies Table) , is expressed as a function of drug diffusivity (A), transendothelial permeability (B), and capillary volume fraction (C). Parameter values cover a range of 2 orders of magnitude below to above those of FGF2 in the heart. FGF2 diffu-sivityϭ0.02 m 2 /s and clearance constants k were empirically verified, and transendothelial permeability was derived from Equation 2 in the Table. Capillary volume fraction ( mv ) was varied over 3 log orders between the extremes of ischemic and normal tissue vascularity. 25 These relationships are linear in loglog scale axes, demonstrating adherence to power law functions.
that the transendothelial permeability and ratio of permeability to diffusivity are Ϸ1.9ϫ10 Ϫ3 m/s and 8.8ϫ10 Ϫ6 m Ϫ1 . This estimate is in line with the transendothelial permeability of a molecule with a molecular size of FGF2. 26 Analytic models of drug transport and loss to capillary flow were evaluated across a range of diffusivities, transendothelial permeabilities, and microvascular volume fractions. Steady-state results (Equations VII and IX in the online-only Data Supplement Methods section) were used because equilibrium is rapidly achieved. Penetration depth at steady state increases as the square root of the diffusion coefficient ( Figure 2A ) and decreases as the square root of the transendothelial permeability constant ( Figure 2B ). It is worth contrasting our results with those from systemic drug delivery through an intravascular route, in which tissue absorption is proportional to transendothelial permeability. Increasing transvascular penetration in systemic delivery requires drugs that permeate across the endothelium and interventions that increase, rather than decrease, vascular permeability. [27] [28] [29] Tissues with higher degrees of vascularization, as embodied by the vascular volume fraction, clear drugs faster and have lower steady-state drug penetration ( Figure 2C ). Thus, steady-state drug penetration and distribution are highly dependent on drug diffusivity through tissue and net microvascular clearance, the compounded effect of transendothelial permeability and microvascular volume fraction (Equation 2 in the Table) .
The theoretical reduction in total deposition caused by capillary clearance was calculated (Equation 5 in the Table) and expressed as a function of the clearance rate constant, k (Equations VIII and XII in the online-only Data Supplement). Percentage clearance of drug with coronary perfusion is most sensitive for clearance rate constants ranging between 1ϫ10 Ϫ5 and 1ϫ10 Ϫ2 s Ϫ1 ( Figure 3A) . Notably, our measurement of the clearance rate constant of TR-FGF2 falls within this range, suggesting that FGF clearance is highly sensitive to transendothelial permeability and microvascular volume fraction.
To examine whether the clearance rate constant of FGF might be modulated by altering its physicochemical properties, we used quantitative fluorescence imaging to contrast the distribution of TR-FGF2 alone or in association with SOS. SOS induces FGF dimerization and increases the effective molecular weight of TR-FGF2. 30 The increase in size was confirmed by size-exclusion chromatography and should reduce transendothelial permeability, capillary washout, and effective diffusivity. Indeed, in the absence of coronary perfusion, TR-(FGF2) 2 -SOS penetrated 40% less than TR-FGF2 into the myocardium (40 m, with an effective diffusivity of 0.013Ϯ0.001 m 2 /s), reflecting its increased size (D eff TR-FGF ϭ0.021Ϯ0.001 m 2 /s; Figure 1 versus 3B) . But, the larger compound also was less affected by coronary perfusion, with penetration depth falling only 26% to 30 m and total deposition falling by only 12% (Figure 3B ). The muted sensitivity of TR-(FGF2) 2 -SOS to flow is consistent with the estimated clearance rate constant (kϭ4.37Ϯ0.33ϫ10 Ϫ5 s Ϫ1 ), model predictions ( Figure 3A) , and our hypothesis that larger molecules enter capillaries less readily.
In Vivo Angiogenic Response Limits Drug Distribution
Conventional pharmacokinetic models for drug distribution do not take into account the potential that drugs can alter capillary density, transendothelial permeability, or drug clearance. Yet, angiogenic growth factors such as FGF1 and FGF2 are specifically administered to induce capillary growth, and it would be unreasonable to assume that transendothelial permeability and drug clearance are not similarly modified. Induced neovascularization implies an increase in the density of blood capillaries that could provide negative feedback, limiting growth factor tissue penetration ( Figure 2C ). Our analysis of myocardial drug transport suggests that FGF would be particularly sensitive to induced capillary washout (Figures 1 and 3A) . We tested this hypothesis in vivo using radiolabeled FGF1 ( 35 S-FGF1). TR-FGF2 could not be used in vivo because its labeling intensity is much lower than that of 35 S-FGF1, rendering it virtually transparent at the doses delivered. Notably, ex vivo experiments with 35 S-FGF1 were well explained by the diffusion-clearance model and suggest that the transport parameters estimated for TR-FGF2 are similar to those of 35 
S-FGF1 (online-only Data Supplement).
Heparin-bound biologically active 35 S-FGF1 fractions were isolated, incorporated into heparin Sepharose-alginate wafers that sustain-release FGF1 for over 30 days in vitro and in vivo ( Figure 4B ), and implanted in the pericardial space of ischemic rabbit hearts ( Figure 4A ). FGF1 successfully penetrated 442Ϯ91 m into the myocardium over the first 2 days after release initiation. Yet, despite sustained delivery, penetration regressed over time, falling 5-fold by day 8 (81Ϯ30 m), and remained low through day 31 ( Figure 5A ). Enhanced growth factor clearance was associated with the induction of neovasculature. Two days after device implantation, the fraction of PECAM-1-stained tissue was 56% greater in animals receiving FGF1 (4.4%) compared with baseline density (2.8%) in control animals with identical devices devoid of growth factor (PϽ0.05; Figure 5C ). Neovascularization peaked at day 8 (8.7%), double that from day 2 (PϽ0.01; Figure 5C ), coinciding with the drop in drug distribution. Similarly, the fraction of PECAM-1-stained tissue decreased significantly from day 8 to 31 (Ϫ62%; PϽ0.01; Figure 5C ), most likely from regression of neocapillaries as the concentration of FGF1 becomes subtherapeutic. Examination of drug delivery devices for remaining drug content confirmed that the decreasing myocardial concentrations arose from increasing capillary clearance rather than decreasing drug delivery. None of the delivery devices were depleted of drug, and all continued to release drug with constant flux ( Figure 4B ) after the expected burst release of Ϸ37.5% during the first 6 hours.
Discussion
The potential of angiogenic promoters of endothelial cell growth and neovascularization is well established in cell and tissue culture. 31, 32 However, angiogenic growth factors have yet to produce stable sustained angiogenesis in clinical trials. 8, 10 Although there are undoubtedly biological factors involved, 33 our study suggests that fundamental transport barriers, particularly the self-limiting pharmacokinetics of angiogenic therapy, also may impair the realization of sustained neovascularization.
Our results reveal that drug transendothelial permeability plays a vital role in governing drug distribution. Lower transendothelial permeability ensures greater myocardial drug penetration after local application ( Figure 2B ). FGF is an arterial vasodilator, but this cannot explain our results because expected changes in arteriolar volume 34 could not reach the scale of our results or explain the difference in growth factor distribution between perfused and static flow conditions, both of which saw growth factor. The dependence of drug distribution on transendothelial permeability and capillary density takes on further complexity for angiogenic compounds that can remodel their tissue environment. Over the course of treatment, vessel density in ischemic tissues increases in FGF1-laden tissue regions (within 500-to 600-m depth from epicardium; Figure 5B ). Indeed, abundant neovascularization occurs from day 2 to 8, but drug washout rises as well, precipitously dropping the local tissue concentration of FGF1 ( Figure 5A ) and penetration depth of FGF1 despite no quantifiable change in growth factor delivery. The instability of FGF1 in the absence of heparin 35 cannot account for the observed effects because the factor was released directly from the heparin Sepharose devices to the epicardial tissue. Released FGF1 likely binds reversibly to myocardial heparin sulfate proteoglycans, prolonging its tissue half-life. Indeed, angiogenic activity was observed 8 days after delivery ( Figure 5 ). Moreover, changes in angiogenic action correlated with regression of FGF1 distribution, not a decrease in activity or stability. Continuum pharmacokinetics (Equation XV of the online-only Data Supplemental Methods) suggest a 5-fold increase in capillary washout between day 2 and 8. Such an increase in the FGF1 clearance could arise from an increase in microvascular density and/or transendothelial permeability (Equation 2 in the Table) . The observed 65% rise in capillary density between days 2 and 8 indicates that the latter plays a dominant role and suggests that the induced vasculature is immature and highly permeable to FGF1.
Our findings, therefore, offer possibilities for engineering drugs to penetrate tissue better by reducing their transendothelial permeability. FGF2 lies within the region where drug penetration depth is highly sensitive to the clearance rate constant, k ( Figure 4A ), which is directly proportional to transendothelial permeability (Equation 2 in the Table) , whereas (FGF2) 2 -SOS, with its 2.6-times-lower clearance, is less affected by flow. More than 50% of FGF2 but only 12% of (FGF2) 2 -SOS is cleared by coronary perfusion (Figure 1  versus 3B ). Therefore, one way to decrease permeability is to consider drugs of higher molecular weight. Although higher molecular weight implies lower myocardial drug diffusivity, the ratio of permeability to diffusivity can drop 2 orders of magnitude as molecular radius increases from 2.4 to 36 Å. 26 A different method for modulating transendothelial permeability is by modification of drug charge. Indeed, it has been shown that negatively charged dextrans exhibit 10-times- lower transendothelial permeability than neutral analogs. 36 This approach may present a method for lowering transendothelial permeability of a drug to increase penetration depth and deposition.
Our study also highlights the impact of capillary clearance on myocardial drug distribution and elimination and sets a ceiling for the depth of drug penetration at steady state. Such clearance is dependent on the transendothelial permeability of the delivered drug and tissue vascularity. At normal arterial PO 2 , a significant portion of capillaries are relatively constricted. Normal myocardium can respond swiftly to arterial hypoxia through active hyperemia by dilating capillaries and effectively decreasing the intercapillary distance and thus the oxygen diffusion barrier. 37 Through reactive hyperemia, the glycocalyx lining of endothelial cells can be modified by reactive oxygen species to increase transendothelial permeability and capillary and postcapillary venule diameter. 38 However, myocardial capillary density declines markedly with ischemia and infarction, limiting capillary reserve. 39 -41 Because capillaries act as spatially distributed sinks to drug, myocardium with denser functional vascularity will clear drug more efficiently and rapidly, creating zones of low drug concentration. Gradation in vascularity in diseased tissue thus has important consequences for local drug delivery. Because capillary flow in ischemic and infarcted regions is substantially lower than in normal tissue, our data predict that drug penetration would be greater. Placing delivery devices directly in the ischemic region should confer the pharmacoki-netic advantages of decreased capillary washout; in wellperfused regions, drug molecules may never reach ischemic areas at sufficient levels. Pericardial delivery of growth factors to target endocardial ischemic regions may thus prove futile because drugs will not easily cross well-perfused epicardial regions. Indeed, drug penetration in the presence of capillary perfusion was limited ex vivo ( Figure 1 ) and in vivo ( Figure 5 ) despite ample time for distant diffusion.
The integrated studies presented suggest that angiogenesis is powerfully self-regulating in that the very capillaries induced by angiogenic drug therapy may increase clearance. The pharmacodynamic changes during the early angiogenic therapy can tip the pharmacokinetics to conditions that are unfavorable for growth factor penetration, which in turn affects long-term therapeutic goals. This mechanism implies a natural upper limit effect for pharmacological revascularization, which restricts angiogenic drug penetration and spatially confines the sprouting of new vessels near the drug source. At day 31, the FGF1 level in the 100-to 500-m tissue region falls to undetectable levels, and significant regression of neovascularization consequently occurs in the absence of local growth factor ( Figure 5C ). One might well imagine that such forces are essential to endogenous regulation of tissue morphogenesis and repair and that loss of such regulation may help explain the growth of vascular tumors and other arteriovenous malformations and anomalies.
The interdependence of the pharmacokinetics and pharmacodynamics elucidated in this study may explain the diffi- culty of realizing the clinical potential of angiogenic compounds and suggests that efficacy becomes critically dependent on device placement and the transendothelial permeability of the drug. The quantitative framework presented here may help guide rational selection of angiogenic compounds based on a favorable physicochemical profile and drug delivery strategies that take advantage of the regulation between growth factor pharmacokinetics and angiogenic pharmacodynamics.
